Hsbc Holdings PLC bought a new position in shares of Bruker Corporation (NASDAQ:BRKR – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 88,647 shares of the medical research company’s stock, valued at approximately $5,252,000. Hsbc Holdings PLC owned approximately 0.06% of Bruker as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently made changes to their positions in the company. Royal Bank of Canada increased its position in Bruker by 8.3% during the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after buying an additional 9,501 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Bruker in the first quarter valued at approximately $262,000. Goldman Sachs Group Inc. grew its position in shares of Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after acquiring an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Bruker by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after acquiring an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth increased its holdings in shares of Bruker by 115.0% in the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock valued at $469,000 after acquiring an additional 6,008 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.
Bruker Stock Down 6.8%
Shares of Bruker stock opened at $54.43 on Thursday. The company has a market cap of $8.29 billion, a P/E ratio of -77.76, a PEG ratio of 1.79 and a beta of 1.26. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. Bruker Corporation has a one year low of $30.09 and a one year high of $65.30. The firm has a fifty day moving average of $58.57 and a two-hundred day moving average of $49.11.
Bruker Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be given a dividend of $0.05 per share. The ex-dividend date is Monday, September 21st. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker’s payout ratio is presently -28.57%.
Analysts Set New Price Targets
A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research note on Monday, August 31st. Guggenheim upped their target price on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. TD Cowen reiterated a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. JPMorgan Chase & Co. raised their price target on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Finally, Stifel Nicolaus set a $50.00 price target on Bruker in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $57.00.
Check Out Our Latest Analysis on Bruker
Bruker Profile
Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.
Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.
In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.
Featured Articles
- Five stocks we like better than Bruker
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR – Free Report).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
-tbk-logo-1200x675.png){kind=logo}
